248 related articles for article (PubMed ID: 24427314)
21. LRRK2 R1441G in Spanish patients with Parkinson's disease.
Mata IF; Taylor JP; Kachergus J; Hulihan M; Huerta C; Lahoz C; Blazquez M; Guisasola LM; Salvador C; Ribacoba R; Martinez C; Farrer M; Alvarez V
Neurosci Lett; 2005 Jul; 382(3):309-11. PubMed ID: 15925109
[TBL] [Abstract][Full Text] [Related]
22. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player.
Häbig K; Walter M; Poths S; Riess O; Bonin M
Neurogenetics; 2008 May; 9(2):83-94. PubMed ID: 18097693
[TBL] [Abstract][Full Text] [Related]
23. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.
Xiromerisiou G; Hadjigeorgiou GM; Gourbali V; Johnson J; Papakonstantinou I; Papadimitriou A; Singleton AB
Eur J Neurol; 2007 Jan; 14(1):7-11. PubMed ID: 17222106
[TBL] [Abstract][Full Text] [Related]
24. Parkinson's Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32.
Gonzalez-Cano L; Menzl I; Tisserand J; Nicklas S; Schwamborn JC
Mol Neurobiol; 2018 Apr; 55(4):3490-3498. PubMed ID: 28508149
[TBL] [Abstract][Full Text] [Related]
25. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
[TBL] [Abstract][Full Text] [Related]
26. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
27. Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease.
Desplats P; Patel P; Kosberg K; Mante M; Patrick C; Rockenstein E; Fujita M; Hashimoto M; Masliah E
Mol Neurodegener; 2012 Sep; 7():49. PubMed ID: 23017109
[TBL] [Abstract][Full Text] [Related]
28. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
[TBL] [Abstract][Full Text] [Related]
29. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls.
Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
Neurobiol Aging; 2015 Feb; 36(2):1105-9. PubMed ID: 25475535
[TBL] [Abstract][Full Text] [Related]
30. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
[TBL] [Abstract][Full Text] [Related]
31. Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models.
Sloan M; Alegre-Abarrategui J; Wade-Martins R
Biochem Soc Trans; 2012 Oct; 40(5):1080-5. PubMed ID: 22988869
[TBL] [Abstract][Full Text] [Related]
32. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
Ruiz-Martínez J; de la Riva P; Rodríguez-Oroz MC; Mondragón Rezola E; Bergareche A; Gorostidi A; Gago B; Estanga A; Larrañaga N; Sarasqueta C; López de Munain A; Martí Massó JF
Mov Disord; 2014 May; 29(6):750-5. PubMed ID: 24357540
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-599 regulates the development of Parkinson's disease through mediating LRRK2 expression.
Wu Q; Xi DZ; Wang YH
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):724-731. PubMed ID: 30720180
[TBL] [Abstract][Full Text] [Related]
35. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
[TBL] [Abstract][Full Text] [Related]
36. Brain transcriptomic profiling in idiopathic and LRRK2-associated Parkinson's disease.
Botta-Orfila T; Sànchez-Pla A; Fernández M; Carmona F; Ezquerra M; Tolosa E
Brain Res; 2012 Jul; 1466():152-7. PubMed ID: 22634372
[TBL] [Abstract][Full Text] [Related]
37. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity.
Gorostidi A; Ruiz-Martínez J; Lopez de Munain A; Alzualde A; Martí Massó JF
Neurogenetics; 2009 Apr; 10(2):157-9. PubMed ID: 19020907
[TBL] [Abstract][Full Text] [Related]
38. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
[TBL] [Abstract][Full Text] [Related]
39. Mouse models for LRRK2 Parkinson's disease.
Xu Q; Shenoy S; Li C
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
[TBL] [Abstract][Full Text] [Related]
40. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
